About

Kiran joined Mercia in 2021 as an Investment Manager within the Midlands Engine Investment Fund (MEIF), focussing on investing into proof of concept and early-stage companies.

Previous experience

Before joining Mercia, Kiran spent the last three years at the Housing Growth Partnership, making equity investment alongside Midlands based start-ups and SMEs in the Real Estate sector. Kiran has also worked in Lloyds Bank’s Corporate Banking team, providing debt solutions to pan-sector commercial clients, prior to which he graduated with a degree in Business and Management and an MBA.

 

 

 

About

Julian joined the Group in 2016 and is the Investment Principal for EIS with responsibility for the wider Midlands region. His focus is to invest in high-growth technology businesses across the whole of the area, with a particular focus on the Software & the Internet, and the Electronics, Materials, Manufacturing & Engineering sectors. Julian currently sits on the Board of W2 Global Data, VoxPopMe and Living Map.

Previous experience

Prior to joining the Mercia, Julian was a partner with Technology Venture Partners LLP based in Bristol, which managed the South West Ventures Fund (SWVF). The SWVF primarily invested in early-stage technology-focused businesses and university spinouts in software, electronics, medical diagnostics, telematics and semiconductors. He was an associate director for KPMG Corporate Finance in London and Sydney between 2000 and 2006.

julian.dennard@mercia.co.uk

Biography

Mark has extensive private investment and scale-up experience. Since co-founding Mercia he has led the sales of Hybrid Systems (to Myotec) to create PsiOxus Therapeutics Ltd, Warwick Effect Polymers Ltd (to Polytherics Ltd) to create Abzena plc and led the founding investment in Allinea Software Ltd (sold to ARM). Prior to Mercia, Mark played a leading role within Oxford University Innovation (“OUI”, the technology transfer operation of the University of Oxford), spinning out BioAnalab (sold to Millipore), Oxford Immunotec (listed on NASDAQ), Oxitec (sold to Intrexon) and Natural Motion (sold to Zynga).

Following his time at OUI Mark was the vice president corporate development at Oxxon Therapeutics Inc, prior to its sale to Oxford BioMedica plc. He gained his PhD jointly between the University of Oxford and the University of London (King’s College). Mark also has an MBA from the University of Warwick, is a Sainsbury Management Fellow for Life Sciences and was awarded the 2015 EY Entrepreneur of the Year(regional and national).

In addition to this CEO role Mark is also responsible for the following investments – OXGENE, Psioxus and Medherant.

About

Peter joined the Group in 2015 as Head of Life Sciences & Biosciences, with over 20 years’ experience in this sector, and became Chief Operating Officer in 2018. He is responsible for a number of the life science portfolio investments including Locate Bio, MyHealthChecked plc, Sense Biodetection, Axis Spine Technologies and Medovate and in July 2020 he oversaw the successful exit of The Native Antigen Company.

Peter is the champion of several of our key initiatives and working groups as well as heading up the VCT and EIS divisions of Mercia and is a member of:

Mercia Responsible Investment Committee – a Group-wide team committed to delivering the ESG strategy across the business.

Mercia O2 Committee – offering the benefits of diverse opinions, ideas and points of view.

Mercia Knowledge Committee – a Group wide Information and Data Development team which Peter Chairs.

Previous experience

Peter has been involved with a number of turnarounds and exits within the sector, including the acquisition of Surgicraft’s loss-making business where, as managing director, sales quadrupled within three years and the business was subsequently sold to a private equity backed business and Diagnostic World, a fast-growing diagnostic provider to the NHS.

peter.dines@mercia.co.uk

About

Stephen joined the Group in 2019 as an Investment Director for the Midlands Engine Investment Fund (MEIF) team, focusing on proof of concept and early stage opportunities. Stephen is also a member of the Mercia O2 Committee – offering the benefits of diverse opinions, ideas and points of view.

Previous experience

Graduating from Loughborough University, Stephen has spent the last 10 years supporting Midlands-based businesses in a finance capacity. Prior to joining the Group, Stephen was an investor at the Housing Growth Partnership, investing in small and mid-sized housebuilders across the Midlands. Stephen has also spent time in the Midlands office of Lloyds Bank’s leverage finance team, working on acquisition facilities to support private equity buy outs across a multitude of sectors including telecoms, media and technology, manufacturing, leisure, education, and oil and gas.

stephen.windsor@mercia.co.uk

About

David is an Investment Manager with a focus on investing in proof of concept and early-stage companies as part of the Midlands Engine Investment Fund. His investments to date have been in software and IP-rich technology companies. David sits on the board of a number of companies within Mercia’s wider portfolio.

Previous experience

Prior to joining the Group, David worked at Blue Sky Corporate Finance in an advisory role, assisting small and medium-sized businesses with raising investment and sell-side transactions. He previously worked as a business manager for HSBC Bank, providing debt-based finance to a portfolio of clients.

david.baker@mercia.co.uk